ESTRO 2024 - Abstract Book

S1671

Clinical - Lung

ESTRO 2024

Conclusion:

This study employs a Bayesian adaptive approach to develop and assess a personalized adaptive radiotherapy for NSCLC patients to minimize cardiac toxicity. Bayesian methods offer advanatages in continuous learning, incorporation of prior information as well as expert opinions, and flexible adaptation. Preliminary results show promise in reducing cardiac risk, and ongoing analyses will inform further model refinement and improvement for future patient cohorts.

Keywords: Cardiac toxicity, personalized radiation, NSCLC

References:

1. Banfill, K., et al., Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions. J Thorac Oncol, 2021. 16(2): p. 216-227.

2. Wang, K., et al., Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. J Clin Oncol, 2017. 35(13): p. 1387-1394.

3. Atkins, K.M., et al., Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer. J Am Coll Cardiol, 2019. 73(23): p. 2976-2987.